作者
Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown, K Balakrishnan, T Burton, J Cannon, D Collier, C Coughlan, R D'Souza, E Enobakhare, E Findlay, C Gardiner-Hill, P Gupta, J Helmy, C Helmy, L Hobbs, R Hobbs, S Hood, R Iles, S Kean, S Kwok, P Lacy, I MacIntyre, J Mackay, N Markandu, U Martin, L McCallum, G McCann, A McGinnis, V Melville, S Muir, KS Myint, S Nazir, J Palmer, R Papworth, K Rutkowski, M Saxena, A Schumann, H Soran, A Stanley, S Thom, A Webb, C White, R Wilson, A Zak
发表日期
2018/6/1
期刊
The lancet Diabetes & endocrinology
卷号
6
期号
6
页码范围
464-475
出版商
Elsevier
简介
Background
In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension.
Methods
PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites in 314 patients with resistant hypertension. Patients were given 12 weeks of once daily treatment with each of placebo, spironolactone 25–50 mg, bisoprolol 5–10 mg, and doxazosin 4–8 mg and the change in home systolic blood pressure was assessed as the primary outcome. In our three substudies, we assessed plasma aldosterone, renin, and aldosterone-to-renin ratio (ARR) as predictors of home systolic blood pressure, and estimated prevalence of primary aldosteronism (substudy 1); assessed the effects …
学术搜索中的文章
B Williams, TM MacDonald, SV Morant, DJ Webb… - The lancet Diabetes & endocrinology, 2018